

PRESS RELEASE

Lund, Sweden, July 11, 2022

## Spago Nanomedical issues shares to guarantors following the completed rights issue

**Spago Nanomedical AB (publ) (“Spago Nanomedical” or “the Company”) today announces that the Company's Board of Directors, with the support of the authorization given at the Annual General Meeting on May 18, 2022, has resolved to issue 1,079,161 shares as remuneration to a number of guarantors in the rights issue of shares completed in June 2022, in accordance with the guarantee agreements.**

The guarantors who secured the rights issue of shares had the possibility to choose to have the remuneration paid out in cash or in the form of newly issued shares in the Company, as previously communicated in connection with the rights issue. In total, ten guarantors, among them Peter Lindell, Eva Redhe and Mikael Lönn together with a number of investors, have chosen to have the remuneration paid out in shares. Due to this, the Company's Board of Directors has today, with the support of the authorization given at the Annual General Meeting on May 18, 2022, resolved to issue 1,079,161 shares as remuneration to these guarantors, which will increase the Company's share capital by SEK 1,079,161. The reasons for the deviation from the shareholders preferential right is to make a successful capital raise possible, as well as broaden the Company's shareholder structure with these investors, and by this fulfill the guarantee agreements.

The shares are issued at a price of SEK 1.20 per share, corresponding to the issue price in the rights issue and is thus deemed as coherent to market terms according to the Board's assessment. All of the shares in the directed issue have been subscribed and allocated, and the Board of Directors have resolved that payment should be made by the offset of guarantors' claims on the Company amounting to a total of SEK 1.3 M. When these 1,079,161 shares, together with the 48,682,275 shares issued in the rights issue, have been registered with the Swedish Companies Registration Office, the number of shares in the Company will amount to 90,943,723 shares, and the Company's share capital to SEK 90,943,723. The additional dilution, as the result of the directed issue to the guarantors, amounts to 1.19 percent after the right issue has been registered. The Company has not had any specific costs related to the directed issue as it is conducted as part of the work with the rights issue. However, the cash remuneration to guarantors that the Company has to pay decreases to SEK 3.3 million, from the previous maximum of SEK 4.4 million.

Erik Penser Bank is the financial advisor and Cederquist is the legal advisor to Spago Nanomedical in connection with the Rights Issue.

---

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, [mats.hansen@spagonanomedical.se](mailto:mats.hansen@spagonanomedical.se)

---

*Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical's share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see [www.spagonanomedical.se](http://www.spagonanomedical.se).*

*FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, [info@fnca.se](mailto:info@fnca.se).*

---

**Spago Nanomedical issues shares to guarantors following the completed rights issue**